Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
E.l.f. Beauty Fiscal Q2 Adjusted Earnings, Revenue Rise; Lifts Fiscal 2027 Guidance

E.l.f. Beauty Fiscal Q2 Adjusted Earnings, Revenue Rise; Lifts Fiscal 2027 Guidance

MT newswireMT newswire2026/11/04 21:50
05:50 PM EST, 11/04/2026 (MT Newswires) -- E.l.f. Beauty (ELF) reported fiscal Q2 adjusted earnings late Wednesday of $1.21 per diluted share, up from $0.68 a year earlier. Analysts polled by FactSet expected $0.59. Revenue for the quarter ended Sept. 30 rose to $520.8 million from $343.9 million a year earlier. Analysts expected $473.5 million. For fiscal 2027, the company now expects adjusted EPS of $3.82 to $3.86 on revenue of $2.00 billion to $2.03 billion. The company previously expected adjusted EPS of $3.50 to $3.55 on revenue of $1.94 billion to $1.97 billion. Analysts expect $3.67 and $1.98 billion, respectively. Shares of the company rose about 4% in after-hours trading.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss